Introduction
Interferons (IFNs) are a family of biological response modi®ers with a broad spectrum of action such as antiviral eects, immunoregulation and suppression of cell growth (Sen and Lengyel, 1992; Lengyel, 1993) . It is well known that IFNs can eectively inhibit the growth of certain types of cancer, and they have already been used for therapeutic purposes (Gutterman, 1994) . IFN-a is now considered the treatment of choice for chronic myeloid leukemia and hairy cell leukemia (Gutterman, 1994) . Although IFN-a can induce marked improvement including complete remission in patients with these diseases, there are many problems to be resolved such as numerous adverse eects and drug resistance (Einhorn and Grander, 1996) . To understand the mechanism of IFN action is critical to resolving these problems. However, the mechanism of the antiproliferative eect of IFNs is still a subject of current investigation.
Regarding the mechanisms of growth suppression, IFNs have been reported to induce down-regulation of c-myc (Einat et al., 1985) , dephosphorylation of the retinoblastoma susceptibility gene product (pRB) (Resnitzky et al., 1992) , inhibition of both cyclins and cyclin-dependent kinases (CDK) in their expression and activities (Thomas, 1988; Yamada et al., 1994) , induction of CDK inhibitors (Chin et al., 1996; Sangfelt et al., 1997) and modulation of E2F activity (Melamed et al., 1993) . IFNs can also suppress the signaling pathway of growth factors such as plateletderived growth factor and interleukin-6, which may contribute to growth inhibition of factor-dependent cells (Xu et al., 1994) . Although it is ®rmly established that these events are involved in the antiproliferative eect of IFN, further studies are required to elucidate their molecular basis fully.
E2F is a heterodimeric transcription factor originally identi®ed as an element needed for the E1A-dependent activation of a speci®c adenoviral E2 promoter. It is composed of two structurally related subunits, termed E2F and DP (Slansky and Farnham, 1996) . Each subunit is encoded by gene families, and to date, ®ve distinct E2F family members (E2F-1 to E2F-5) and at least two DP genes (DP-1 and DP-2) have been identi®ed (Slansky and Farnham, 1996) . It has been demonstrated that E2F plays an integral role in cell cycle progression by regulating the expression of genes required for S phase entry, including those involved in DNA synthesis (e.g. dihydrofolate reductase, DNA polymerase a and thymidine kinase), cell cycleregulatory genes (e.g. cyclin A, cyclin E and cdc2), and proto-oncogenes (e.g. c-myc, c-myb and B-myb) (Furukawa et al., 1994 and for review see Nevins, 1992) . E2F is now considered a target of RB family proteins including p107, p130 and pRB itself in their activity as tumor suppressors (Beijersbergen and Bernards, 1996) . Binding of underphosphorylated RB family proteins turns active E2F factors into transcriptional repressors, thereby suppressing expression of target genes and cell cycle progression (Weintraub et al., 1995; Chow and Dean, 1996) . Phosphorylation of RB family proteins by CDK/Cyclin complexes results in the release of free E2F, which in turn activates transcription of target genes and facilitates S phase entry. Also, E2F and DP proteins, especially E2F-1 and E2F-4, are known to be phosphorylated by CDK/ Cyclin complexes and other unidenti®ed kinases in a cell cycle-dependent manner, although the signi®cance of this phenomenon remains to be determined (Iwase et al., unpublished observations and Kitagawa et al., 1995; Vairo et al., 1995) .
Previously, we demonstrated that IFN-a was capable of down-regulating E2F-1 mRNA prior to inhibition of cell growth, while E2F-4 mRNA expression was unaected . Given that E2F plays a central role in cell cycle regulation, our ®ndings may be important for understanding the molecular basis of the antiproliferative action of IFN-a more precisely. In this work, we investigated the mechanisms of downregulation of E2F-1 mRNA by IFN-a with a special reference to its eects on the E2F-1 promoter. We found that IFN-a suppressed E2F-1 promoter activity through up-regulation of E2F-4 protein and induction of E2F-4/pRB and E2F-4/p130 complexes, which act as transcriptional repressors.
Results

IFN-mediated growth suppression is closely associated with down-regulation of E2F-1
Among hematopoietic cell lines, Daudi is the most sensitive to IFN-a and easily arrests in G0/G1 phase of the cell cycle in response to a relatively small amount of IFN-a. Recently, we established an IFN-resistant subline, Daudi-R by long term exposure of IFN-a to parental Daudi cells (hereinafter referred to as Daudi-S for discrimination). Daudi-R was found to be 1610 4 times more resistant to IFN-a than Daudi-S by regrowth assay (data not shown). Using these cell lines, we examined whether down-regulation of E2F-1 mRNA was linked to IFN-induced growth suppression. As shown in Figure 1c , [ 3 H]thymidine incorporation, a reliable marker of cell proliferation , of Daudi-S cells was reduced to approximately 60% of the untreated control after 24 h of culture with 250 IU/ml IFN-a and cell growth almost ceased after 48 h. In contrast, no signi®cant eect was observed in Daudi-R cells with the same treatment. During the culture, total cellular RNA was serially isolated from both cell lines, and subjected to Northern blot analysis for E2F-1 mRNA expression. Levels of E2F-1 transcript started to decline in Daudi-S cells after 6 h of culture with IFN-a, and became almost undetectable after 48 h (Figure 1a) . In Daudi-R cells, E2F-1 mRNA expression marginally decreased after 6 ± 12 h of IFN treatment coincident with a minor decrease in cell proliferation, but recovered after 48 h as cells continued to grow. The change in E2F-1 mRNA levels was well-correlated with that of E2F-1 protein detected by Western blotting: E2F-1 protein was diminished in Daudi-S cells after 12 h of culture with IFN-a and disappeared after 48 h, while no signi®cant decrease was observed in Daudi-R cells (Figure 1b) . These results indicate that IFN-mediated growth suppression is closely associated with down-regulation of E2F-1 mRNA.
IFN-induced suppression of the E2F-1 promoter is mediated through its E2F-binding sites
In an attempt to examine how IFN-a suppresses E2F-1 mRNA expression, we ®rst investigated the mechanisms of transcriptional regulation of the E2F-1 gene. Previous studies have demonstrated that 5'-untranslated region up to 7220 is sucient for full promoter activity (Johnson et al., 1994; Neuman et al., 1994) . This region contains putative binding sites for MBF-1 (at 7197 to 7191), Sp1 (at 7187 to 7182, 7167 to 7162, 7154 to 7149, and +29 to +34), and NF-kB (at +3 to +10). Two canonical CAAT boxes are located at 7111 to 7107 and 768 to 764, whereas neither a TATA motif nor an initiator element is present. In addition, there are two palindromic E2F-binding sites at 735 to 724 and 718 to 76 ( Figure  2 ). To initially evaluate the role of these sites in the regulation of the E2F-1 promoter, we constructed four wild-type (WT) reporter plasmids as illustrated in Figure 2 . The WT-220 construct contains the sequence between 7220 and +61 that corresponds to a minimal promoter of the E2F-1 gene. Sp1 cluster, two CAAT boxes and E2F-binding sites were deleted in the WT-147, WT-61 and WT-3 constructs, respectively. In addition, we prepared two mutant constructs, MT-220 and MT-61, which contain nonbinding mutations at the E2F sites (TTTCGCGGCAAAAAGGATTTGG-CGC GTA AA?TTTCGAAG CAAAAAGGA TTTG-GAGCGTCCA) as described in Materials and methods. These reporter plasmids were transiently transfected into Daudi-S cells by electroporation, and CAT activity was assayed after a 24 h culture. As depicted in Table 1 , the WT-220 construct exhibited strong promoter activity comparable to that of pCATcontrol vector, which possesses SV40 promoter with enhancer, in the absence of IFN-a. Deletion of Sp1 cluster at 7187 to 7149 resulted in a marked decrease (about 1/10) in E2F-1 promoter activity. The activity was almost completely abrogated by further deletion of two CAAT boxes (4.1% of the control). In contrast, the introduction of nonbinding mutation at the E2F sites did not aect the promoter activity (108% of the control). These results indicate that E2F-1 promoter is positively regulated by upstream activation sequences (UAS) composed of Sp1 cluster and CAAT boxes, while downstream E2F-binding sites are not involved in steady-state activation.
Next, we examined the eects of IFN-a on E2F-1 promoter activity. Daudi-S cells were transfected with reporter plasmids, cultured in the presence of IFN-a and harvested for CAT assays after 24 h. IFN-a was able to suppress the E2F-1 promoter signi®cantly, i.e. CAT activities of both WT-220 and WT-147 constructs were reduced to 25% of those obtained in the absence of IFN-a (Table 1) . It is of note that deletion of Sp1 cluster did not aect the inhibitory eect of IFN. However, mutation at the E2F sites almost completely abolished IFN-induced inhibition of the E2F-1 promoter (% inhibition was less than 15% in both MT-220 and MT-61 constructs). This suggests that IFN suppresses the E2F-1 promoter through downstream E2F-binding sites but not upstream activation sequences.
E2F-4 is the major E2F species bound to the E2F-1 promoter and is also a relevant target of IFN Then, we attempted to identify the molecules actually bound to the E2F-1 promoter and to investigate how IFN modulates them. We ®rst screened the binding of transcription factors to the E2F-1 promoter by DNase I footprinting. Figure 3 displays a representa- Figure 2 Schematic representation of the E2F-1 promoter constructs used in this study. 5'-untranslated sequences of the E2F-1 promoter (up to 7220, 7147, 761 and 73 relative to the transcription start site) were linked to the CAT gene in pCATbasic vector as indicated. Relative locations of the putative binding sites of known transcription factors and CAAT boxes were approximated by the symbols shown in the box. Mutations were introduced into two E2F-binding sites in MT-220 and MT-61 constructs (indicated by asterisks) 9.3 11.9 a The structure of the reporter plasmids is illustrated in Figure 2 . Repression of E2F-1 transcription by interferon-a Y Furukawa et al tive result of this approach using nuclear extracts from Daudi-S cells. Binding of transcription factors, as detected by protection from DNase I cleavage or hypersensitivity, was observed at the MBF-1 site, two of three upstream Sp1-binding sites, and one of two CAAT boxes ( Figure 3 , left panel). Moreover, strong protection was notable over the sequences spanning two palindromic E2F-binding sites (P-3 in the right panel of Figure 3 ). From these results, we provisionally concluded that these sites were actually involved in regulation of the E2F-1 promoter. Side-by-side comparison of the results from untreated cells and IFN-treated cells revealed that IFN-a did not alter the occupancy of the promoter signi®cantly [IFN(7) vs IFN(+) in Figure 3 ]. This suggests that the eect of IFN-a on the E2F-1 promoter is mainly qualitative and/or quantitative change is not strong enough to aect the patterns of footprinting. It is possible that IFN changes the species of E2F bound to the promoter (e.g. from E2F-1 to E2F-4), or modulates their subunit composition.
Based on this assumption, we sought to ®nd the species of E2F molecules bound to the E2F-1 promoter and the eects of INF-a on them. Electrophoretic mobility shift assay was employed for this purpose using double-stranded oligonucleotide containing two E2F-binding sites of the E2F-1 promoter (739 to 72) as a probe. As shown in Figure 4a , multiple DNA-protein complexes were detectable with this probe in Daudi-S and Daudi-R cells before and after IFN treatment. Five distinct bands (designated as A to E) were found to be speci®c E2F complexes, since they were competed out by the addition of unlabeled E2F consensus oligonucleotides, whereas no eect was observed with a mutated E2F oligonucleotide (Figure 4b ). On the other hand, the fastest migrating band was considered to be non-speci®c (indicated by an asterisk in Figure 4 ). In untreated Daudi-S cells, there were three speci®c E2F complexes (C, D and E). Addition of anti-E2F-4 antibody completely supershifted band C, which stuck on top of the gel (Figure 4d ). This band was not aected by speci®c antibodies against other E2F family members (anti-E2F-1 and anti-E2F-5) or those against RB family proteins (anti-pRB, anti-p107, and anti-p130). Furthermore, DOC treatment did not abolish band C (Figure 4c ), indicating that it corresponds to free (uncomplexed) E2F-4. The identity of the other two complexes (D and E) is to be determined, since no signi®cant change was induced by any antibodies used in this study. It is worth noting that E2F-1 is not included in these complexes despite the abundance of E2F-1 protein in untreated Daudi-S cells. IFN-a increased the amounts of C and D slightly, and also induced two novel complexes, A and B, in Daudi-S cells [IFN(+) of Figure 4a , left panel]. Cold competition and DOC disruption experiments clearly demonstrated that both A and B were speci®c and higher-order protein complexes (Figure 4b and c). These changes were not observed in IFN-resistant Daudi-R cells ( Figure 4a , right panel), suggesting that these are speci®c for IFN-induced growth inhibition. Complexes A and B were identi®ed as E2F-4/p130 and E2F-4/pRB by antibody perturbation experiments: anti-E2F-4 supershifted both A and B, and anti-p130 and antipRB eliminated A and B, respectively, whereas antibodies against E2F-1, E2F-5, and p107 had no eects ( Figure 4d ). Taken together, these results suggest that transcriptional repression of the E2F-1 gene by IFNa is mediated through recruitment of E2F-4/pRB and E2F-4/p130 complexes to the downstream negativeregulatory element of the E2F-1 promoter.
IFN was capable of inducing up-regulation of E2F-4 protein and dephosphorylation of pRB and p130
Finally, we investigated the molecular basis of IFNmediated formation of E2F-4/pRB and E2F-4/p130 complexes. Both Daudi-S and Daudi-R cells were cultured with IFN-a for up to 24 h, and whole cell lysates were isolated at given time points and subjected to Western blot analysis for E2F-4 expression. Before IFN treatment, E2F-4 protein was discernible as three bands of varying electrophoretic mobilities that most likely re¯ect dierential phosphorylation ( Figure 5 ). Peptide blocking revealed that all three bands really represent speci®c E2F-4 proteins ( Figure 5 , second row). There was much less E2F-4 than E2F-1 in untreated, cycling Daudi cells (compare Figures 1b and  5) . However, the amount of E2F-4 greatly increased in Daudi-S cells after 12 h of culture with IFN-a and became dominant over E2F-1 after 24 h. Immunoperoxidase staining revealed that the majority of the increased E2F-4 protein was in the nucleus of IFNtreated cells (data not shown). It should be noted that, among three distinct bands, IFN-a selectively increased the most slowly migrating form, which may correspond to hyperphosphorylated species of E2F-4 (Vairo et al., 1995) . Up-regulation of E2F-4 was not detectable in IFN-resistant Daudi-R cells, suggesting that this phenomenon is causally linked to the antiproliferative action of IFN-a. In addition, E2F-5 protein, another member of the E2F family with similar properties to E2F-4 (Hijmans et al., 1995) , was not inducible by IFN-a ( Figure 5 ). These results strongly suggest that E2F-4 is speci®cally involved in growth inhibition by IFN. Expression of Sp1, which plays a crucial role in positive regulation of the E2F-1 promoter through binding to the UAS, was not aected by IFN consistent with the results of DNase I footprinting in Next, we examined the expression and phosphorylation status of RB family proteins using the same samples. As is clearly shown in Figure 6 , pRB was present almost exclusively in heavily phosphorylated forms in both Daudi-S and Daudi-R before IFN treatment, re¯ecting the active proliferative status of these cells (Furukawa et al., 1992; Iwase et al., 1997) . In Daudi-S cells, IFN-a was capable of accumulating an underphosphorylated form of pRB after 12 h of treatment, and most RB protein became dephosphorylated after 24 h (Figure 6 ). Similarly, dephosphorylation of p130 became apparent after 24-h culture with IFN-a in Daudi-S cells. In contrast, little if any dephosphorylation of pRB and p130 was observed in Daudi-R cells, indicating that these changes are closely related to growth inhibition. The amount of p107, another member of the RB family, was reduced in Daudi-S cells during culture with IFN-a, and it was slightly up-regulated in Daudi-R cells (Figure 6 ). This may simply re¯ect the changes in cell cycle status of target cells, i.e. the levels of p107 expression are generally low in G0/G1 phases and increase as cells enter S phase Smith et al., 1996) .
Formation of active E2F-4/pRB and E2F-4/p130 complexes in vivo after IFN treatment As a result of dephosphorylation, pRB and p130 can bind to E2F family proteins eciently (Kaelin et al., 1992) . E2F-4 is the predominant species of E2F proteins in IFN-treated cells due to selective upregulation as described above. Therefore, it appears these changes facilitate the formation of E2F-4/pRB and E2F-4/p130 complexes, which in turn bind to the E2F-binding sites of the E2F-1 promoter. To con®rm this hypothesis, we ®rst performed sequential immunoprecipitation-immunoblot analysis. Whole cell lysates from untreated and IFN-treated Daudi-S cells were subjected to immunoprecipitation with either antipRB, anti-p107, or anti-p130 monoclonal antibody, and each immune complex was resolved on SDS ± PAGE gels, followed by blotting with anti-E2F-4 polyclonal antibody. As shown in Figure 7 , E2F-4 protein was appreciably detected in anti-pRB and antip130 immunoprecipitates from IFN-treated cells. In contrast, E2F-4 was not present in anti-p107 immunoprecipitate from IFN-treated cells. E2F-4 was not detectable in any sample from untreated Daudi-S cells. Additionally, we performed immunoprecipitation-DOC release assays to con®rm that active E2F-4 protein made a complex with pRB and p130. E2F gel shift assays were carried out with pRB-, p107-and p130-associated proteins from IFN-treated cells after disruption of higher-order protein complexes by DOC. As shown in Figure 8 , an E2F complex was recovered from anti-pRB and anti-p130 immunoprecipitates but not from anti-p107 precipitate. Anti-E2F-4 antibody almost completely eliminated this complex (Figure 8 ), indicating that E2F-4 was a dominant species of E2F in a complex with pRB and p130 in IFN-treated Daudi-S cells. Neither E2F-4/pRB nor E2F-4/p130 was detectable by the same approach in Daudi-R cells before and after IFN treatment (data not shown). Taken together, these results convincingly demonstrate that IFN induces formation of active E2F-4/pRB and E2F-4/p130 complexes in vivo. Previous studies showed that underphosphorylated RB family proteins, upon binding to E2F, switch E2Fs from transcriptional activators to repressors (Weintraub et al., 1995; Chow and Dean, 1996) . This notion allows us to conclude that IFN-induced E2F-4/pRB and E2F-4/p130 complexes repress the E2F-1 promoter upon binding to its downstream negative regulatory element.
Discussion
Recently, we found that E2F was a signi®cant target of antiproliferative action of IFN: down-regulation of E2F-1 was associated with IFN-mediated growth inhibition, while E2F-4 mRNA expression was unaected . In this work, extending the previous study, we investigated the mechanisms of IFN-induced suppression of the E2F-1 gene, although it is possible that post-transcriptional mechanisms such as increased turnover of mRNA are also involved in down-regulation of E2F-1 transcript. For this purpose, we ®rst examined the structure-function relationship of the E2F-1 promoter and its regulatory mechanisms. Transfection studies using proliferating Daudi cells revealed that steady-state transcription of the E2F-1 gene was primarily driven by an upstream Sp1 cluster and two canonical CAAT boxes. Introduction of nonbinding mutation at downstream E2F sites did not aect E2F-1 promoter activity in cycling cells, suggesting that E2F is not involved in transactivation. The importance of Sp1 cluster in activation of the E2F-1 promoter has been reported by researchers who carried out genomic cloning of the E2F-1 gene (Johnson et al., 1994; Neuman et al., 1994) . They also described that E2F sites conferred cell cycledependent regulation of E2F-1 mRNA expression, suggesting that E2F-1 gene is under`autoregulatory' control. These ®ndings indicate that E2F-1 promoter is functionally divided into two parts: upstream activation sequences (UAS; Sp1 cluster and CAAT boxes) and a downstream negative-regulatory element (E2F-binding sites). Interestingly, this structure-function relationship shares signi®cant similarities with other genes involved in cell cycle control such as cdc2 (Dalton, 1992; Furukawa et al., 1994) , cyclin A (Henglein et al., 1994) and cdc25c . All three genes are TATA-less, and driven by a UAS composed of Sp1 cluster and a reverse CAAT box, with which NF-Y transcription factor is proposed to interact. Additionally, KraÈ mer et al. (1996) reported that a novel CAAT-binding protein CBP/cycA was necessary for adhesion-inducible transcription of Daudi-S cells were subjected to immunoprecipitation with antipRB, anti-p107, and anti-p130 antibodies. Precipitated immune complexes were used for electrophoretic mobility shift assays with E2F-1 promoter oligonucleotide as a probe after disruption of higher-order protein complexes by DOC. Assays were carried out in the absence (7) or presence (+) of anti-E2F-4 antibody cyclin A. Identi®cation of CAAT box-binding factor for E2F-1 is currently underway in our laboratory. With this background in mind, we attempted to determine whether the UAS or E2F-binding site is a target of IFN action. We found that IFN markedly reduced E2F-1 promoter activity, but this inhibition was completely abrogated by non-binding mutation at the E2F sites. In contrast, deletion of Sp1 cluster did not aect the inhibitory eect of IFN. Moreover, DNase I footprinting revealed that IFN did not alter the occupancy of either Sp1-binding sites or CAAT boxes. Therefore, IFN-induced suppression of E2F-1 is likely to be mediated through downstream E2F sites but not UAS. Recently, Zwicker et al. (1995) identi®ed a common mechanism of transcriptional repression of cell cycle regulatory genes whose activation is dependent on UAS. They found that inhibitory elements, termed CDE (cell cycle-dependent element) and CHR (cell cycle genes homology region), are located in the region of the basal promoter of some cell cycle regulatory genes (e.g. cdc2, cyclin A and cdc25c). The CDE/CHR may interfere with the interaction between UAS-associated activators and the basal transcriptional machinery, thereby repressing transcription. In the case of cyclin A and cdc25c, CDE/CHRbinding factors have not yet been identi®ed and E2F does not seem to occupy this site, although their CDE/ CHR sequences bear weak similarity with an E2F-binding consensus. On the other hand, it was shown that E2F-4/p130 complex bound to the CDE/CHR of the cdc2 promoter and acted as a transcriptional repressor (Tommasi and Pfeifer, 1995) . In the E2F-1 promoter, instead of CDE/CHR sequence, canonical E2F-binding sites are located at the nucleotide positions between 739 and 72 where TATA motif is supposed to be present and confer cell cycledependent regulation of the E2F-1 gene. Our study strongly suggests that this site is also responsible for IFN-mediated repression of E2F-1. We therefore tried to determine the molecules on the E2F sites of E2F-1 promoter and the eects of IFN on them with DNase I footprinting and electrophoretic mobility shift assays.
Free E2F-4 was found to be the predominant species on the E2F sites in proliferating Daudi cells, although signi®cant amounts of E2F of unknown identity were observed as well. The occupancy of E2F-binding sites was not changed when cell growth was arrested by IFN. This is typical of classical E2F sites where E2F complexes bind throughout the cell cycle (Zwicker et al., 1996) . There is a growing appreciation that E2F-dependent regulation of target genes can be classi®ed into two types (Nevins, 1992; Slansky and Farnham, 1996) . First, when target genes are positively regulated by their E2F elements, transcriptionally-active E2F (mainly E2F-1) binds to the promoter, coincident with the accumulation of free E2F, and facilitates gene activation at late G1 phase of the cell cycle (positive regulation). This type of regulation was observed in the genes involved in DNA synthesis such as dihydrofolate reductase, thymidine kinase, DNA polymerase a, proliferating cell nuclear antigen, and cyclin E (DeGregori et al., 1995; Geng et al., 1996) . Alternatively, E2F elements act primarily on suppression of transcription during G0 to G1 phases for some growth-promoting genes such as B-myb, c-myc, cdc2, and HsOrc1 (Lam and Watson, 1993; Tommasi and Pfeifer, 1995; Ohtani et al., 1996) . In this case, E2F sites are occupied by E2F in a complex with RB family proteins, which act as transcriptional repressors (Weintraub et al., 1995; Chow and Dean, 1996) , in a quiescent state. Upon mitogenic stimulation, RB family proteins are phosphorylated by cyclin-dependent kinases and liberated from E2F at late G1, thereby allowing derepression of target genes and S phase entry (negative regulation). Based on the data presented here and elsewhere (Johnson et al., 1994; Neuman et al., 1994) , E2F-1 is considered to be regulated according to the latter model. At present, we cannot provide a good explanation of why free E2F-4 on the E2F-1 promoter is not actively involved in positive regulation of the E2F-1 gene. It can be speculated that E2F-4 merely acts to facilitate interaction between the UAS and basal transcription machinery by bending DNA (see below), and is dispensable for the interaction itself in this promoter context. Further investigation of the general mechanisms of E2F-mediated gene activation is required to resolve this issue.
We found that IFN-a was capable of inducing upregulation of E2F-4 along with dephosphorylation of pRB and p130, which in turn resulted in the formation of E2F-4/pRB and E2F-4/p130 complexes on the E2F-1 promoter. As previously demonstrated for other promoters (Weintraub et al., 1995; Chow and Dean, 1996) , these complexes may function as transcriptional repressors to inhibit E2F-1 mRNA expression. This is in good agreement with previous observations that E2F-4 was expressed in early phases of the cell cycle (Sardet et al., 1995) and was the predominant species found in E2F complexes involved in negative regulation of the B-myb and HsORC1 promoters (Lam and Watson, 1993; Ohtani et al., 1996) . Indeed, it has been reported that E2F-4-containing complexes accumulate in cells treated with transforming growth factor-b, another universal negative regulator of cell growth (Li et al., 1997) . Moreover, E2F-4 was found to be the most abundant E2F species in terminally-dierentiated blood cells, which naturally arrest in G0/G1 phases of the cell cycle (Vairo et al., 1995; Williams et al., 1997a) . Taken together, these results suggest that E2F-4 is a relevant target for both inducible and intrinsic growth arrest. In this context, it is reasonable to speculate that up-regulation of E2F-4 plays a crucial role in the antiproliferative eect of IFN. To our knowledge, this is the ®rst report demonstrating E2F-4 as a direct mediator of IFN action. However, up-regulation of E2F-4 per se is not sucient for transcriptional repression, since E2F-1 promoter activity was not inhibited by forced expression of E2F-4 in Daudi-S cells (data not shown). This suggests that the increased E2F-4 primarily acts as a reservoir for dephosphorylated pRB and p130. Previously, we described that IFN did not aect the expression of E2F-4 mRNA, whereas down-regulation of E2F-1 occurred within the same period . Therefore, the increase in E2F-4 protein may be due to enhanced translation and/or inhibition of protein degradation. Recently, it has been shown that degradation of E2F proteins is executed by the ubiquitin-proteasome pathway and phosphorylation of E2F may modify this process (Hofmann et al., 1996) . Precise analysis on the mechanisms of IFN-mediated induction of E2F-4, including the eects on ubiquitin-dependent proteoly-sis, is currently underway in our laboratory. Also, it should be noted that IFN selectively increased the most highly phosphorylated form of E2F-4. Although phosphorylation of E2F-4 has been described by other researchers and is shown to vary with the status of cell growth, its signi®cance remains to be determined (Vairo et al., 1995) . Hence, our ®nding may be helpful in elucidating the role of E2F-4 phosphorylation in growth regulation. A recent report by Williams et al. (1997b) provides evidence to support this notion in natural occasion: E2F-4 was abundant in G1-arrested hematopoietic progenitor cells and was present almost exclusively in hyperphosphorylated forms. Given that IFN is an intrinsic regulator of hematopoietic progenitor cells (Selleri et al., 1996) , it is highly likely that E2F-4, upon induction and phosphorylation by intrinsic IFN, mediates cell cycle arrest of these cells. Consistent with this view, E2F-1 mRNA was not expressed in freshly-isolated hematopoietic progenitor cells, and became readily detectable during culture with hematopoietic growth factors (Furukawa et al., unpublished observation) . Suppression of E2F-1 may be attributable to intrinsic IFNs in these cells.
Finally, we examined how E2F-4/pRB and E2F-4/ p130 complexes repress transcription from the E2F-1 promoter, and what the role of free E2F-4 is during steady cell growth. An elegant study by Tao et al. (1997) provided an important clue as to how to address these questions. They de®ned consensus sequences for preferential binding of E2F complexes with dierent subunit compositions, such as E2F-4/DP-1 and pRB/ E2F-1/DP-1, by the CASTing (cyclic ampli®cation and selection of targets) procedure. According to their results, the sequence corresponding to the E2F-binding site at 718 to 711 (TTTGGCGC) of the E2F-1 promoter was preferentially selected by either pRBcontaining E2F complex (20 out of 51 isolates) or E2F-4/DP-1 (17/51), whereas the frequency of the binding of E2F-1/DP-1 and E2F-1/DP-2 to the same sequence was much lower (5/51 and 6/51, respectively). In contrast, another E2F-binding site of the E2F-1 promoter at 735 to 728 (TTTCGCGG) may not be functional, because only two out of a total of 169 isolates matched this consensus sequence. In addition, they found that almost all of the E2F-4/DP-1 and pRB-containing E2F complexes bound to palindromic E2F-binding sites (90% and 100% of isolates from the CASTing experiments, respectively). These results explain why E2F-4 but not E2F-1 selectively binds to the palindromic E2F sites of the E2F-1 promoter irrespective of protein abundance. Previously, we and others reported that IFN-treatment of Daudi cells resulted in inhibition of DNA binding activity of E2F (Melamed et al., 1993; Iwase et al., 1997) . These studies were conducted with probes containing dierent E2F motif from that of the E2F-1 promoter. The discrepancy between previous studies and the present ®nding may be explained by the recognition motif preference of E2F molecules. Functionally, free E2F-4 was capable of bending DNA with a mean bend angle of 23 degrees upon binding to the sequence TTTGGCGC, and this bending was reversed by pRB binding (bend angle; 9+2 degrees). This hypothesis is supported by previous studies of other groups (Huber et al., 1994; Cress and Nevins, 1996) . Based on these ®ndings, we propose a model of E2F-1 regulation by IFN as illustrated in Figure 9 . When cells actively proliferate, free E2F-4 binds to the E2F-1 promoter Figure 9 Model for E2F-1 regulation by IFN. See Discussion for details. The abbreviations used are: E2F, E2F-binding sites; CAAT, CAAT box-binding factor of unknown identity; pRB-phos and p130-phos, hyperphosphorylated pRB and p130, respectively; pRB and p130, underphosphorylated pRB and p130, respectively and facilitates interaction between the UAS and transcription initiation complex by bending DNA, although E2F-4 binding may be dispensable for the interaction itself (Figure 9 , upper panel). IFN induces up-regulation of E2F-4 and dephosphorylation of pRB and p130, which result in the formation of E2F-4/pRB and E2F-4/p130 complexes on the palindromic E2F-binding sites. These complexes reverse DNA bending, thereby interfering with the interaction required for transactivation of the E2F-1 gene (Figure 9 , lower panel). In conclusion, these results indicate that E2F-4 is a critical regulator of E2F-1 and the E2F-1 gene is not under`autoregulatory' control as proposed previously (Johnson et al., 1994; Neuman et al., 1994) . Besides E2F, a number of transcription factors, such as STAT and GATA, constitute a family of proteins that recognize a cognate binding motif. Our present ®ndings may oer an excellent paradigm for understanding the functional diversity within a family of transcription factors.
Materials and methods
Reagents
Highly puri®ed natural IFN-a derived from Sendai virusinfected Nawalwa cells was provided by Sumitomo Pharmaceutical Co. Ltd. (Osaka, Japan). Twenty IFN-a components were included in this preparation with speci®c activities of 1.3610 8 to 2.6610 8 IU/mg of protein . All chemical reagents were purchased from Sigma Chemical Co. (St Louis, MO, USA) unless otherwise stated.
Cells and cell culture
Burkitt's lymphoma cell line Daudi was maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS). IFN-resistant subline Daudi-R was established by long-term exposure of IFN-a to Daudi cells as described elsewhere (Iwase et al., submitted for publication) . Cell growth was monitored by pulse labeling the cells for the ®nal 1 h of the culture with 5 mCi/ml of [ 3 H]thymidine (Amersham Corp., Arlington Heights, IL, USA).
Northern blotting
Total cellular RNA was isolated by cesium chloride centrifugation using CS120FX ultracentrifuge and S100AT5 ®xed-angle rotor (Hitachi Koki, Co. Ltd.). An equal amount (10 mg) of the samples was electrophoresed in 1% agarose gels containing 6% formaldehyde, 20 mM MOPS, 5 mM sodium acetate and 1 mM EDTA, and blotted onto Hybond N + synthetic nylon membranes (Amersham Corp.). The membranes were hybridized with full length E2F-1 cDNA probe (provided by Drs William G Kaelin Jr, James A DeCaprio and David M Livingston, Dana-Farber Cancer Institute, Boston, MA, USA), which was labeled with 32 P-dCTP (DuPont-NEN) by using the oligonucleotide random priming method (Furukawa et al., 1994) .
Immunoprecipitation and Western blotting
Cells were washed with ice-cold TBS buer (25 mM TrisHCl, pH 8.0, 150 mM NaCl), and lysed in EBC buer (50 mM Tris-HCl, pH 8.0, 120 mM NaCl, 0.5% nonidet P-40, 100 mM sodium¯uoride, 200 mM sodium orthovanadate) in the presence of protease inhibitors (Furukawa et al., 1992) . Immunoprecipitation was conducted as previously described . Whole cell lysates (40 mg each) or immunoprecipitates (from 300 mg lysates) were separated on 6, 7.5 or 10% SDS-polyacrylamide gels (0.166.568.5 cm) and transferred onto Immobilon-P polyvinylidene di¯uoride membranes (Millipore Corp., Bedford, MA, USA). After blocking in TBS buer containing 10% nonfat dry milk, 1% bovine serum albumin and 0.05% Tween 20 for 16 h, the membranes were incubated for 1 h with the following antibodies at a ®nal concentration of 1 mg/ml (except 250 ng/ml for antip130): anti-E2F-1 polyclonal antibody (C-20), anti-E2F-4 polyclonal antibody (C-108), anti-E2F-5 polyclonal antibody (E-19), anti-pRB monoclonal antibody (PMG3-245), anti-p107 monoclonal antibody (SD9), anti-p130 monoclonal antibody (clone 10), anti-Sp1 polyclonal antibody (PEP2), and anti-b-actin monoclonal antibody (Ab-1). All antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) except anti-pRB from Pharmingen (San Diego, CA, USA), anti-p130 from Transduction Laboratories (Lexington, KY, USA) and anti-b-actin from Oncogene Science (Uniondale, NY, USA). The membranes were developed with the enhanced chemiluminescence system (Amersham Corp.) after incubating with horseradish peroxidase-conjugated secondary antibody diluted 1 : 1000 with 0.016blocking buer for 1 h.
For peptide neutralization, anti-E2F-4 antibody C-20 (Santa Cruz Biotechnology) was incubated with a tenfold weight excess of blocking peptide (sc-866P, Santa Cruz Biotechnology) for 16 h at 48C, diluted in 0.16blocking buer and then used for immunoblotting.
Immunoperoxidase cell staining
Immunoperoxidase staining of cytospin specimens was carried out with the ImmunoCruz staining system (Santa Cruz Biotechnology) according to the manufacturer's instruction.
Reporter plasmids
The deleted E2F-1 promoter fragments were generated by polymerase chain reaction (PCR) based on the reported sequence of the E2F-1 gene (Johnson et al., 1994; Neuman et al., 1994) . PCR products (up to 7220, 7147, 761, and 73 relative to the transcription start side; 3'-end is at the nucleotide position of +61) were subcloned into pCRII TA cloning vector (Invitrogen, San Diego, CA, USA). A HindIII/XbaI fragment from these clones was linked to the chloramphenicol acetyltransferase (CAT) gene in pCATbasic vector (Promega, Madison, WI, USA) as illustrated in Figure 2 . The structure of all constructs was veri®ed by direct DNA sequencing. pCAT-control vector (Promega), which contains SV40 promoter and enhancer sequences, was used as a positive control. b-Galactosidase expression vector (pSV-b-gal, Promega) was used to monitor transfection eciencies. All plasmids were puri®ed twice by cesium chloride gradient ultracentrifugation, linearized by appropriate restriction enzymes and puri®ed again by ethanol precipitation before transfection.
PCR site-directed mutagenesis
Mutation was introduced into the putative E2F-binding sites of E2F-1 promoter constructs by PCR site-directed mutagenesis according to the method of Landt et al. (1990) . Brie¯y, ®rst PCR was carried out in a reaction mixture containing 1 ng of the WT-220 plasmid (Figure 2 ) and 1 mM each of the mutagenesis primer (5'-CTCTTTCGAAGCAAAAAGGATTTGGAGCGTCCAG -TGGCCG-3', mutated sites are shown in boldface italics) and the reverse primer (corresponding to the nucleotides between +41 and +61 of the E2F-1 gene) with 15 cycles of denaturation at 948C for 1 min, annealing at 458C for 1 min and polymerization at 728C for 45 s. The yielded 100 bp fragment was puri®ed by agarose gel electrophoresis and used as the intermediate primer in second PCR with the forward primer (corresponding to the nucleotides between 7220 and 7201 for MT-220, and those between 761 and 742 for MT-61). Second PCR was done with 30 cycles of denaturation at 948C for 1 min, annealing at 608C for 1 min and polymerization at 728C for 1 min. The resulting products were subcloned into pCAT-basic vector as described above to generate MT-220 and MT-61 plasmids (Figure 2) . Loss of E2F binding to the sequence in these constructs was con®rmed by electrophoretic mobility shift assays (data not shown).
Transient transfection and CAT assay
Plasmids were introduced into Daudi cells by electroporation (Furukawa et al., 1996) . Brie¯y, cells (2610 7 cells/ transfection) were resuspended in 500 ml of RPMI 1640 medium containing 20% FCS with 40 mg of linearized plasmid DNA (36 mg of reporter plasmids and 4 mg of pSV-b-gal), and an electropulse was delivered at 250 V, 960 mF by using a Gene Pulser apparatus (Bio-Rad). The cells were placed on ice for 15 min, resuspended at 5610 5 cells/ml in RPMI 1640 containing 10% FCS, and split equally into two¯asks. IFN-a was added into one¯ask at a ®nal concentration of 250 IU/ml. Whole cell extracts were prepared after 24 h of the culture, and the protein concentration was determined by the Bradford method (Bradford, 1976) . CAT activities were quantitatively assayed by the liquid scintillation counting method with 50 mg of each sample (Seed and Sheen, 1988) . Each result was normalized for transfection eciencies determined by co-transfected b-galactosidase activities. Relative CAT activity was expressed as % control with the activity of pCAT-control set at 100% as previously described (Furukawa et al., 1996) .
In vitro DNase I footprinting
A 306 bp DNA fragment was isolated from pCRII vector containing the E2F-1 promoter sequence (7220 to +61) by sequential digestion with KpnI and NotI and labeled with 32 P-dCTP at the NotI site (sense strand) by E. Coli DNA polymerase I Klenow fragment. Nuclear extracts (80 mg) were incubated with approximately 2 ng (15 000 c.p.m.) of the probe and 1 mg of poly (dA-dT) (Pharmacia-LKB, Uppsala, Sweden) in 10 mM HEPES, pH 7.9, 0.1 mM EDTA, 0.5 mM dithiothreitol, 10% glycerol and 2% polyvinyl alcohol on ice for 20 min. The protein-DNA complexes were treated with 0.25 U of DNase I (Stratagene, La Jolla, CA, USA) at room temperature for 2 min. The reaction was terminated by the addition of 100 ml of DNase I stop solution (200 mM NaCl, 20 mM EDTA, 1% SDS and 40 mg/ml tRNA). DNA was extracted with phenol/chloroform, precipitated with ethanol and resuspended in 4.5 ml loading buer (7M urea, 0.05% xylene cyanol and 0.05% bromophenol blue in 0.16Tris borate-EDTA buer). The probe was treated with 0.0125 U of DNase I without nuclear extracts in otherwise the same manner and used as a control (naked DNA). Maxam and Gilbert sequencing reactions of the same DNA were used as size standards. The samples were denatured at 958C for 3 min and applied to 12% polyacrylamide/7M urea gels (21640 cm, 0.4 mm thick).
Electrophoresis was carried out in 16Tris borate-EDTA buer at 30 W for 1 h.
Electrophoretic mobility shift assay
